LogicBio Therapeutics (LOGC) – Globe Newswire
-
LogicBio Therapeutics to Present at Upcoming Investor Conferences
-
LogicBio Therapeutics to Present at Upcoming Investor Conferences
-
LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
-
LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
-
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
-
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
-
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
-
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
-
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
-
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
-
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
-
LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020
-
LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020
-
LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
-
LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
-
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
-
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
-
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
-
LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference
-
LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference
-
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
-
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
-
LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors
-
LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates
-
LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates
-
LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors
-
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
-
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
-
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
-
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
-
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
-
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
-
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candi
-
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ C
-
LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates
-
LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates
-
LogicBio Therapeutics to Present at November Conferences
-
LogicBio Therapeutics to Present at November Conferences
-
LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress
-
LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress
-
LogicBio Therapeutics to Present at October Conferences
-
LogicBio Therapeutics to Present at October Conferences
-
LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates
Back to LOGC Stock Lookup
